CytoAgents’ Phase 1 Trial Results Show “Cytokine Release Syndrome” Drug Candidate Safe

Successful Completion of Phase 1 Clinical Trial, Close of Initial Equity Round of Funding, and Addition of Dr. Stanley Marks and John Friedman to Board of Directors Positions CytoAgents for Larger Series A and Phase II Trials. Read more >>